title: Early renal replacement therapy during pediatric cardiac extracorporeal support increases mortality.
abstract: BACKGROUND
  Acute kidney injury is a common comorbidity for children placed on extracorporeal membrane oxygenation (ECMO) because of primary cardiac disease. Continuous venovenous hemofiltration (CVVH) can optimize fluid status and lessen inflammatory response during ECMO. However, published data are derived primarily from children without primary cardiac disease.
  
  
  METHODS
  A retrospective analysis of our institutional ECMO database from 2002 to 2011 was performed. To limit the bias that CVVH initiation was after evidence of end-organ injury, we considered "early CVVH" to be instituted within 48 hours of ECMO initiation. Multivariate logistic regression was undertaken to adjust for covariates.
  
  
  RESULTS
  Of 153 cardiac ECMO patients, 59 (39%) received early CVVH. Time from ECMO initiation to CVVH initiation was 1.7±0.7 days (median 1 day). Pre-ECMO and post-ECMO serum creatinine levels were similar in both groups. However, peak serum creatinine was 1.1±0.4 mg/dL (median 1.0 mg/dL) in the ECMO and CVVH group and 0.9±0.4 mg/dL (median 0.8 mg/dL) in the ECMO alone group (p=0.003). Patients who received CVVH had a higher mortality (p<0.0001), were less likely to have had ECPR (p=0.004), and had a longer duration on ECMO (p<0.0001). In multivariate analysis subjects receiving CVVH support within 48 hours of ECMO cannulation were 3 times more likely to die during their hospitalization (odds ratio 3.02; 95% confidence interval 1.32 to 6.9, p=0.009) after adjusting for other significant risk factors.
  
  
  CONCLUSIONS
  Early CVVH in pediatric cardiac patients requiring ECMO is associated with increased mortality. Early CVVH in the cardiac ECMO population does not appear justified.
authors.affiliation: Department of Pediatrics, Division of Pediatric Cardiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA. wolfm@kidsheart.com
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wolf
authors.forename: Nikhil K
authors.initials: NK
authors.lastname: Chanani
authors.forename: Micheal L
authors.initials: ML
authors.lastname: Heard
authors.forename: Kirk R
authors.initials: KR
authors.lastname: Kanter
authors.forename: William T
authors.initials: WT
authors.lastname: Mahle
mesh_terms: D058186:Acute Kidney Injury / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D002423:Cause of Death; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D016208:Databases, Factual; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006440:Hemofiltration / Q000009:adverse effects* / Q000379:methods; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007677:Kidney Function Tests; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003404:Creatinine
keywords: 27